ASX Announcement August 20, 2021

IND CLEARANCE RECEIVED FROM THE US FOOD AND DRUG ADMINISTRATION (FDA) FOR CHM 1101 (CLTX CAR T) FOR GLIOBLASTOMA

- First IND clearance received from US FDA for CHM 1101 (CLTX CAR T) for patients with recurrent and progressive Glioblastoma
- Provides the foundation for advancing development of CHM 1101
- Enables expansion of the CHM 1101 phase 1 clinical trial to additional sites

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical-stage cell therapy company, is pleased to announce that the US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for CHM 1101 (CLTX CAR T) for patients with recurrent/relapsed Glioblastoma.

CHM 1101 (CLTX CAR T) is a novel CAR T cell therapy that uniquely utilizes Chlorotoxin as its tumour targeting domain. CHM 1101 has shown promising preclinical safety and efficacy and is currently being studied in a single site phase 1 clinical trial.

"The FDA clearance of our IND is a critical milestone for Chimeric as it enables us to expand the development program for CHM 1101 (CLTX CAR T)," said Jennifer Chow, COO Chimeric Therapeutics. "Our first step will be to open new phase 1 clinical trial sites under the current study protocol. This will allow us to accelerate the phase 1 CHM 1101 clinical trial, which will be particularly important as we head towards the expansion phase of the protocol."

With this foundational IND, Chimeric will also further advance plans for a phase 1 basket trial in solid tumours and a phase 2 registration trial in Glioblastoma.

Chlorotoxin is derived from scorpion toxin, which binds preferentially to unique targets on brain cancer cells. CLTX CAR T cells do not target healthy cells and has not elicited adverse side effects when delivered intracranial and through IV routes in brain cancer mouse models. At the same time it has shown to bind to a higher percentage of Glioblastoma tumours than immunotherapies against other targets. Glioblastoma is the most common and aggressive type of brain tumour, with overall survival following first recurrence estimated at only 5-8 months.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM). CHM 1101 was developed by scientists at the City of Hope Medical Centre in California where it is currently being studied in a phase 1 clinical trial.

Chimeric also recently announced the expansion of its pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors
Jennifer Chow
Chief Operating Officer
Chimeric Therapeutics
P: +9087238387
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au